DSIP · delta sleep-inducing peptide · onset · timeline · research use only
How Long Does DSIP Take to Work? The Timeline from the Research
DSIP (Delta Sleep-Inducing Peptide) is a nonapeptide with the sequence WAGGDASGE, first isolated from the cerebral venous blood of sleeping rabbits by Monnier and Schoenenberger in 1977. The key timing question — how quickly does it act? — has two distinct answers depending on which effect you are measuring. The 1981 Schneider-Helmert IV administration study documented an almost immediate subjective 'feeling of sleep pressure,' with a 59% increase in total sleep time within a 130-minute monitoring window. The 1992 Bes study in chronic insomniacs showed shorter sleep latency and higher sleep efficiency versus placebo across nights, suggesting a sleep-architecture reorganisation that accrues across multiple sessions. These are two different clocks worth separating. This page is general educational context about a research compound. Titan Peptide Lab supplies DSIP as a nasal spray for laboratory and research use only — not for human use, not as a sleep aid, not as medical advice.
Acute clock: 'sleep pressure' within minutes (Schneider-Helmert 1981)
The oldest and most-cited timing data comes from Schneider-Helmert & Schoenenberger 1981 (Eur Neurol, PMID 6895513) — a study of six healthy subjects given DSIP by IV infusion. The subjects immediately reported a 'feeling of sleep pressure' after administration, and polysomnographic recordings showed that total sleep time increased by approximately 59% within a 130-minute monitoring interval. This is the acute-onset clock: the subjective experience of sedation/drowsiness begins within minutes of IV administration, and the sleep-architecture change is measurable within roughly two hours. The caveat is significant: the dataset is six subjects, the administration was intravenous (not nasal), and DSIP has a plasma half-life of only 15 minutes — meaning the intact peptide clears before the sleep window even opens, which makes the mechanism of sustained action an unresolved question.
DSIP tolerability data →Sleep-architecture clock: shorter latency across nights (Bes 1992)
A different picture emerges from the Bes et al. 1992 study (PMID 1299794), which enrolled chronic insomniacs in a placebo-controlled design. DSIP improved sleep efficiency and shortened sleep latency compared to placebo — effects that were measured across sleep sessions rather than within a single 130-minute window. This 'multi-night architecture' clock is distinct from the Schneider-Helmert acute-onset observation. One interpretation: DSIP may shift underlying sleep-regulatory set-points over time — consistent with the hypothesised role of the nonapeptide in sleep homeostasis — rather than simply acting as a pharmacological sedative. The mechanism for this is unresolved: DSIP has no identified gene or confirmed receptor, and its effects outlast its plasma half-life by a factor that preclinical kinetics alone cannot explain.
Peptides for sleep research overview →The half-life paradox: 15 minutes in blood, effects for hours
DSIP's plasma half-life when exposed to proteolytic enzymes is approximately 15 minutes. In the 1981 Schneider-Helmert IV study, the intact peptide would have been largely cleared from circulation within 30–45 minutes of administration — well before the bulk of the sleep-time increase was recorded. This is not unique to DSIP (several neuropeptides show this pattern), but the mechanism by which a 15-minute plasma peptide influences sleep architecture for 60–130 minutes is genuinely unresolved. Candidate explanations include: CSF binding and prolonged central exposure after peripheral clearance; downstream neuromodulatory effects triggered during the brief intact-peptide window; or metabolic fragments with their own activity. None of these is confirmed in the published record.
DSIP pharmacokinetic reference →Nasal route vs IV: the data gap
Both the Schneider-Helmert 1981 and Bes 1992 studies used intravenous administration — not nasal spray. Titan supplies DSIP as a nasal spray, and the pharmacokinetic profile of intranasal DSIP has not been published in a peer-reviewed PK study. Nasal bioavailability of nonapeptides varies widely depending on molecular weight, lipophilicity, mucociliary clearance, and enzymatic activity in the nasal mucosa. DSIP (MW ~848 Da, moderate polarity) is within the size range where partial nasal absorption is feasible, but there is no published Tmax, Cmax, or bioavailability comparison for intranasal DSIP vs IV. This is a meaningful data gap: any timing estimate for nasal DSIP is extrapolated from IV data, not directly measured.
DSIP nasal spray sourcing →The circadian and GH-release angle
Beyond sleep architecture, DSIP research has also tracked its interaction with the circadian axis — specifically, GH (growth hormone) secretion during slow-wave sleep. Iyer, Marks, Kastin & McCann 1988 (PNAS 85:3653-3656) documented that DSIP enhanced slow-wave sleep and the associated sleep-related GH pulse in their model. This suggests DSIP may act partly through coordinating circadian timing rather than simply inducing sedation. The implication for timing: the relevant 'clock' for the GH/circadian effect may be measured not in minutes but in sleep cycle structure — whether slow-wave sleep appears earlier, lasts longer, or is denser after DSIP exposure. This is a different endpoint than sleep latency, with its own timeline and its own lack of confirmed mechanism.
DSIP research dosing reference →What this timeline does and does not mean
The timing data above applies to IV administration in small human populations (n=6 in the 1981 study; not n=6,000). Intranasal DSIP timing is extrapolated, not measured. The 'feel of sleep pressure within minutes' observation comes from one study in six people, is IV-route-specific, and has not been replicated in a larger, modern, placebo-controlled RCT. The multi-night sleep efficiency finding (Bes 1992) is from a small controlled study in insomniacs. Neither study is sufficient to establish DSIP's human efficacy in the absence of modern ICH-GCP trial evidence. Titan supplies DSIP as an RUO laboratory material, not for use as a sleep peptide, supplement, or therapeutic. This page is a plain account of what the published literature studied and when — not a protocol or recommendation.
Sleep peptide research overview →DSIP onset — two clocks, sourced
Acute subjective onset vs sleep-architecture efficiency: distinct timelines, honest caveats.
Both IV administration data. Intranasal timing is extrapolated, not directly measured. These are research parameters, not dosing instructions.
- Immediate: acute sleep pressure
- 'Subjects immediately reported a feeling of sleep pressure.' IV administration, n=6. Source: Schneider-Helmert & Schoenenberger 1981 (PMID 6895513). Strongest acute-onset datapoint in the literature.
- Within 130 min: +59% total sleep time
- Polysomnographic recordings showed 59% increase in total sleep time within a 130-minute monitoring window after IV DSIP. Same source. The intact peptide had cleared (~15 min t½) before most of this window.
- Across nights: shorter latency, higher efficiency
- In chronic insomniacs, DSIP produced shorter sleep latency and higher sleep efficiency vs placebo measured across sessions. Source: Bes et al. 1992 (PMID 1299794). A different, slower clock than the acute Schneider-Helmert observation.
- GH/slow-wave timing
- DSIP enhanced slow-wave sleep and associated sleep-related GH pulse in the PNAS model. Source: Iyer, Marks, Kastin & McCann 1988 (PNAS 85:3653-3656). Measured in sleep-cycle structure, not minutes.
- Nasal route timing
- UNKNOWN. No published PK study for intranasal DSIP. Any onset estimate is extrapolated from IV data. Nasal bioavailability of the 848 Da nonapeptide has not been quantified in peer-reviewed research.
Questions researchers ask
Before you order.
- How long does DSIP take to work?
- In the Schneider-Helmert 1981 study of IV DSIP in six healthy subjects, subjects reported an 'immediate feeling of sleep pressure' and total sleep time increased 59% within a 130-minute window. For sleep-architecture effects across nights, the Bes 1992 chronic-insomnia study found shorter sleep latency vs placebo. There is no published PK study for intranasal DSIP, so nasal-route onset is extrapolated rather than measured.
- Why does DSIP seem to work if it clears in 15 minutes?
- This is one of the genuinely unresolved questions in DSIP research. The intact peptide's plasma half-life is approximately 15 minutes, yet sleep effects are measured 60–130 minutes after administration. Proposed explanations include: prolonged CSF binding after peripheral clearance, downstream neuromodulatory effects triggered during the brief intact-peptide window, or active metabolic fragments. None is confirmed. It is similar to the half-life paradox seen in BPC-157: the initiating peptide clears faster than the biological response it triggers.
- Is the DSIP research strong enough to trust?
- The key timing data (Schneider-Helmert 1981) involves six subjects in an IV design. The Bes 1992 insomnia trial is small by modern standards. Neither study used modern ICH-GCP trial design. DSIP's receptor has never been identified, and its gene has not been found in the human genome — making the mechanism genuinely mysterious. The research is intriguing but the evidence base is thin and primarily old. No modern large RCT has replicated these findings.
- Does Titan's DSIP nasal spray have the same timing as IV DSIP?
- Unknown. Titan's DSIP is supplied as a nasal spray. The pharmacokinetics of intranasal DSIP have not been published in a peer-reviewed study. Nasal bioavailability depends on molecular size, charge, enzymatic degradation in nasal mucosa, and mucociliary clearance — variables that have not been measured for this specific compound. Any timing claims for the nasal route are speculative extrapolations from IV data.